By Jeff Somers, For years, the treatment of Alzheimer’s disease focused on symptoms. New research targets the pathophysiological changes underneath — with potentially promising results....

Though many people with insomnia go into doctor’s visits expecting a drug to relieve their sleeplessness, stakeholders are moving increasingly toward holistic approaches. Clinicians, medical...

It is no surprise that sleep problems are on the rise due to life changes caused by the coronavirus disease 2019 (COVID-19) pandemic. Based on my experience, the current environment, with myriad...

Dr. Lynn Kramer, CMO, Eisai Neurology, discusses the FDA’s regulatory pathway allowing for the extrapolation of clinical data from adjunctive to monotherapy use in partial-onset seizures, which improves access to epilepsy treatments.

Human genetics is transforming the way new drugs are discovered, giving unprecedented hope for delivering better medicines